Skip to content
value.today

Apricus Biosciences, Inc.

Formerly Nexmed Inc.

Total raised
$7 M
2 rounds on record
Latest round
$4 M
Sep 2017
First round on record
Sep 2016
Today
Private
See the company page

Apricus Biosciences, Inc. is listed today as Apricus Biosciences: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Apricus Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2017$4 MNo. 2$2 to $10 million

Apricus Biosciences, Inc.: Raise no. 2, Sep 2017

Investors in this round

9 investors had bought by the notice of Sep 27, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$258,370
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian D. Dorsey · Executive Officer
  • Neil D. Morton · Executive Officer
  • Richard W. Pascoe · Executive Officer, Director
  • Kleanthis G. Xanthopoulos · Director
  • Paul V. Maier · Director
  • Rusty W. Ray · Director
  • Sandford D. Smith · Director
  • Wendell W. Wierenga · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. WAINWRIGHT & CO., LLC (CRD 375) · New York, New YorkSold in NY

Signed by Richard W. Pascoe, Chief Executive Officer and Secretary. Newest notice filed Sep 27, 2017. Read the notice at the SEC.

equity, optionsSEC
Sep 2016$4 MNo. 1$2 to $10 million

Apricus Biosciences, Inc.: Raise no. 1, Sep 2016

Investors in this round

2 investors had bought by the notice of Oct 13, 2016: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$327,548
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Nevada

People named in the notice

  • Brian D. Dorsey · Executive Officer
  • Catherine D. Bovenizer · Executive Officer
  • Neil D. Morton · Executive Officer
  • Richard W. Pascoe · Executive Officer, Director
  • Kleanthis G. Xanthopoulos · Director
  • Paul V. Maier · Director
  • Rusty W. Ray · Director
  • Sandford D. Smith · Director
  • Wendell W. Wierenga · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • RODMAN & RENSHAW LLC (CRD 281264) · New York, New YorkSold in FL, IL

Signed by Richard W. Pascoe, Chief Executive Officer and Secretary. Newest notice filed Oct 13, 2016. Read the notice at the SEC.

optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Apricus Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2017).

    SEC Form D · Sep 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2017

Products and services#

No products or services of Apricus Biosciences, Inc. are on record.

Investors#

No investor of Apricus Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Apricus Biosciences, Inc.
NameRoleNamed in
Brian D. DorseyExecutive officerSep 2017
Neil D. MortonExecutive officerSep 2017
Richard W. PascoeExecutive officerSep 2017
Catherine D. BovenizerExecutive officerOct 2016
Kleanthis G. XanthopoulosDirectorSep 2017
Paul V. MaierDirectorSep 2017
Richard W. PascoeDirectorSep 2017
Rusty W. RayDirectorSep 2017
Sandford D. SmithDirectorSep 2017
Wendell W. WierengaDirectorSep 2017